Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
Roy M FleischmannDaniel F AlvarezAmy E BockCarol CronenbergerIvana VranicWuyan ZhangRieke E AltenPublished in: RMD open (2021)
ClinicalTrials.gov identifier: NCT02480153; EudraCT number: 2014-000352-29.